A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Protara Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 336,740 shares of TARA stock, worth $1.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
336,740
Previous 150,400 123.9%
Holding current value
$1.71 Million
Previous $312,000 97.44%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.7 - $2.4 $316,778 - $447,216
186,340 Added 123.9%
336,740 $616,000
Q2 2024

Aug 09, 2024

BUY
$1.96 - $4.14 $128,968 - $272,412
65,800 Added 77.78%
150,400 $312,000
Q1 2024

May 13, 2024

SELL
$1.86 - $4.83 $53,382 - $138,621
-28,700 Reduced 25.33%
84,600 $339,000
Q4 2023

Feb 13, 2024

BUY
$1.12 - $1.93 $59,584 - $102,676
53,200 Added 88.52%
113,300 $212,000
Q3 2023

Nov 14, 2023

SELL
$1.64 - $2.93 $38,540 - $68,855
-23,500 Reduced 28.11%
60,100 $100,000
Q2 2023

Aug 11, 2023

BUY
$2.27 - $3.59 $56,055 - $88,651
24,694 Added 41.92%
83,600 $200,000
Q1 2023

May 12, 2023

SELL
$2.76 - $3.91 $22,339 - $31,647
-8,094 Reduced 12.08%
58,906 $184,000
Q4 2022

Feb 13, 2023

SELL
$2.43 - $3.7 $29,646 - $45,140
-12,200 Reduced 15.4%
67,000 $180,000
Q3 2022

Nov 14, 2022

BUY
$2.96 - $4.27 $74,000 - $106,749
25,000 Added 46.13%
79,200 $234,000
Q2 2022

Aug 12, 2022

BUY
$2.8 - $5.33 $46,480 - $88,478
16,600 Added 44.15%
54,200 $159,000
Q1 2022

May 13, 2022

SELL
$4.19 - $6.9 $113,968 - $187,680
-27,200 Reduced 41.98%
37,600 $192,000
Q4 2021

Feb 11, 2022

SELL
$6.15 - $7.76 $314,265 - $396,536
-51,100 Reduced 44.09%
64,800 $437,000
Q3 2021

Nov 12, 2021

BUY
$6.38 - $9.3 $411,337 - $599,598
64,473 Added 125.37%
115,900 $802,000
Q2 2021

Aug 13, 2021

BUY
$8.68 - $16.99 $173,834 - $340,258
20,027 Added 63.78%
51,427 $501,000
Q1 2021

May 13, 2021

BUY
$13.75 - $23.86 $196,487 - $340,959
14,290 Added 83.52%
31,400 $494,000
Q4 2020

Feb 10, 2021

SELL
$16.97 - $25.34 $350,871 - $523,929
-20,676 Reduced 54.72%
17,110 $414,000
Q3 2020

Nov 13, 2020

BUY
$16.76 - $31.89 $130,728 - $248,742
7,800 Added 26.01%
37,786 $636,000
Q2 2020

Aug 13, 2020

BUY
$22.0 - $60.7 $659,692 - $1.82 Million
29,986 New
29,986 $879,000

Others Institutions Holding TARA

About Protara Therapeutics, Inc.


  • Ticker TARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,267,400
  • Market Cap $57.2M
  • Description
  • Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...
More about TARA
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.